Study of a new combination for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an experimental drug (HC-7366) combined with an approved targeted therapy (belzutifan) for people with advanced kidney cancer. It aims to see if the combination is safe and works better than either drug alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced kidney cancer (cannot be removed with surgery or has spread to other parts of the body).
- Your kidney cancer must be the clear cell type (the most common kind).
- You must be 18 years old or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new drug combinations for people with advanced kidney cancer whose disease returned after a prior immunotherapy. It's designed to find better treatment options for those who have not received other treatments for advanced disease.
This trial tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that returned after or within 2 years of finishing an immunotherapy treatment after surgery. You cannot have received any other cancer treatments besides that immunotherapy.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests a new drug (casdatifan) combined with cabozantinib for advanced clear cell kidney cancer, comparing it to cabozantinib alone. It's for people who haven't taken these specific medicines before and are still in fairly good health.
This study tests an experimental drug (HC-7366) combined with standard immunotherapy for advanced kidney cancer. It aims to see if this combo can help control the cancer better, and checks safety and effectiveness.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.